| Literature DB >> 19165653 |
Dattatreya Mendhekar1, Deep Lohia.
Abstract
Atomoxetine is the only FDA-approved non-stimulant to treat ADHD. We report a case of Atomoxetine-related exacerbation of nocturnal bruxism in a 12-yr old boy with ADHD, subsiding on discontinuing the drug, but re-worsening with retrial, finally subsiding upon adding Buspirone. This is the first report of its kind showing such an association, not included in any pre- or post-marketing data. Clinical implications and possible mechanisms are discussed.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19165653 DOI： 10.1080/15622970802576488
Source DB: PubMed Journal: World J Biol Psychiatry ISSN： 1562-2975 Impact factor: 4.132